The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Improving the cure rate of multiple myeloma
Although the rates of progression-free survival are steadily increasing, the majority of multiple myeloma (MM) patients still face relapse. Here, Niels van de Donk, MD, PhD, of VU University Medical Centre, Amsterdam, Netherlands, considers approaches for improving the cure rate of MM; from introducing earlier more active agents, to achieving measurable residual disease (MRD) negativity. He also highlights promising therapies for future testing. This interview took place at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
